Chromosomal instability predicts metastatic disease in patients with insulinomas. by Jonkers, Y.M.H. et al.
  
 
Chromosomal instability predicts metastatic disease
in patients with insulinomas.
Citation for published version (APA):
Jonkers, Y. M. H., Claessen, S. M. H., Perren, A., Schmid, S., Komminoth, P., Verhofstad, A. A., ... Speel,
E. J. M. (2005). Chromosomal instability predicts metastatic disease in patients with insulinomas.
Endocrine-Related Cancer, 12, 435-447. https://doi.org/10.1677/erc.1.00960
Document status and date:
Published: 01/01/2005
DOI:
10.1677/erc.1.00960
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
Chromosomal instability predicts
metastatic disease in patients
with insulinomas
Y M H Jonkers, S M H Claessen, A Perren1, S Schmid1, P Komminoth2,
A A Verhofstad3, L J Hofland4, R R de Krijger5, P J Slootweg6,
F C S Ramaekers and E-J M Speel
Department of Molecular Cell Biology (Box 17), Research Institute for Growth and Development, University of Maastricht, PO Box
616, 6200 MD, Maastricht, The Netherlands
1Department of Pathology, University Hospital, Zurich, Switzerland
2Department of Pathology, Hospital Baden, Switzerland
3Department of Pathology, University Medical Center, Nijmegen, The Netherlands
4Department of Internal Medicine, University Medical Center, Rotterdam, The Netherlands
5Department of Pathology, University Medical Center, Rotterdam, The Netherlands
6Department of Pathology, University Medical Center, Utrecht, The Netherlands
(Requests for offprints should be addressed to Y M H Jonkers; Email: Y.Jonkers@MOLCELB.unimaas.nl)
Abstract
Endocrine pancreatic tumors (EPTs) comprise a highly heterogeneous group of tumors with
different clinical behavior and genetic makeup. Insulinomas represent the predominant syndromic
subtype of EPTs. The metastatic potential of insulinomas can frequently not be predicted using
histopathological criteria, and also molecular markers indicating malignant progression are
unreliable because of the small number of cases per subtype studied so far. For the identification
of reliable indicators of metastatic disease, we investigated 62 sporadic insulinomas (44 benign and
18 tumors with metastases) by means of comparative genomic hybridization (CGH). In addition, the
role of MEN1 (multiple endocrine neoplasia type 1) gene mutations was determined to assess
specific chromosomal alterations associated with dysfunction of this endocrine tumor-related tumor
suppressor gene. Only one case with a somatic MEN1 mutation was identified (1527del7bp),
indicating that the MEN1 gene plays a minor pathogenic role in sporadic insulinomas. CGH analysis
revealed that the total number of aberrations per tumor differs strongly between the benign and the
malignant group (4.2 vs 14.1; P<0.0001). Furthermore, chromosome 9q gain was found to be the
most frequent aberration in both benign and malignant insulinomas, whereas chromosome 6q
losses and 12q, 14q and 17pq gains are strongly associated with metastatic disease. Our study
shows that chromosomal instability, as defined by ‡5 gains together with ‡5 losses, or total number
of gains and losses ‡8, rather than parameters such as tumor size and proliferation index, is the
most powerful indicator for the development of metastatic disease in patients with sporadic
insulinoma.
Endocrine-Related Cancer (2005) 12 435–447
Introduction
Endocrine pancreatic tumors (EPTs) represent 1–2%
of all pancreatic neoplasms and are separated on the
basis of their clinical manifestation into functioning
(syndrome-related) and non-functioning tumors. Insu-
linomas are the most frequently detected functioning
EPTs. They show evidence of b-cell differentiation and
clinical symptoms of hypoglycemia due to uncon-
trolled insulin production. Strategies for insulinoma
treatment include surgical resection and, in the case of
palliation, chemotherapy and anti-hypoglycemic
medication (Chun & Doherty 2001, Komminoth et al.
2004). The only feature that separates benign from
malignant disease is organ and/or lymph node inﬁl-
tration or distant metastases (Komminoth et al. 2004).
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When only a primary lesion is identiﬁed, however, no
reliable markers for malignancy are available. At best a
tumor diameter ‡2 cm, an increased mitotic index and
necrosis seem to indicate an increased risk for
malignancy (Hochwald et al. 2002). It is obvious that
new indicators that reliably determine prognosis of
malignancy are urgently needed.
Little is known about the molecular pathogenesis of
insulinomas (Leothela et al. 2003, Moore et al. 2003).
So far, only limited numbers of predominantly benign
insulinomas have been genetically analyzed, indicating
the involvement of the MEN1 (multiple endocrine
neoplasia type 1) gene at 11q13, and gain of chromo-
some 9q in early tumorigenesis (Zhuang et al. 1997,
Go¨rtz et al. 1999, Cupisti et al. 2000, Speel et al. 2001).
MEN1 is the susceptibility gene of the autosomal
dominant familial MEN1 cancer syndrome (Schus-
sheim et al. 2001). Patients with an inherited mutation
in this gene develop tumors in endocrine organs,
including insulinomas in 10–35% of cases. Evidence
for a direct involvement of the MEN1 tumor suppres-
sor gene in early insulinoma development was provided
by a transgenic mouse model with a hemizygous
deletion of the MEN1 gene in pancreatic b-cells.
Somatic deletion of the second allele resulted in
insulinoma formation with multiple progression
features (Bertolino et al. 2003). However, a role for the
MEN1 gene in human sporadic insulinomas is unclear.
Its mutation rate seems to be rather low, ranging from
0 to 17% in the different studies described so far
(Zhuang et al. 1997, Go¨rtz et al. 1999, Cupisti et al.
2000, and references therein). On the other hand, we
have recently shown that in a small series of
predominantly benign insulinomas, gain of chromo-
some 9q is the most common alteration identiﬁed by
comparative genomic hybridization (CGH) in 50% of
insulinomas with a diameter £ 2 cm, with the smallest
region of gain being 9q34 (Speel et al. 2001).
Chromosomal markers with high potential to
discriminate malignant from benign insulinomas have
not been described so far. DNA cytometry data
suggest that DNA ploidy is unlikely to provide useful
prognostic information for patients with insulinomas,
because large ploidy changes are seldomly detected
(Graeme-Cook et al. 1990, Bo¨ttger et al. 1997). The
few malignant insulinomas that have been genetically
analyzed by molecular allelotyping and CGH were
mainly part of larger studies on EPTs, including
different functioning and non-functioning subtypes
(Chung et al. 1998, Speel et al. 1999, 2001, Stumpf et al.
2000, Zhao et al. 2001). Several markers for malignant
or metastatic progression in EPTs have been indicated,
in particular loss of chromosomes 1 (Ebrahimi et al.
1999), 3p (Chung et al. 1997, Hessman et al. 1999,
Barghorn et al. 2001a), 3q (Chung et al. 1998, Guo
et al. 2002), 6q22-24 (Barghorn et al. 2001b), 11q13
(Hessman et al. 1999), 17p (Beghelli et al. 1998), 22q
(Chung et al. 1998, Wild et al. 2002) and X (Missiaglia
et al. 2002). These do, however, require further
validation in larger series of individual EPT subtypes,
including insulinomas.
The objective of the present study was to determine
by CGH the occurrence of DNA copy number losses
and gains along all chromosome arms in benign and
malignant insulinomas in order to asses the chromo-
somal markers with the highest potential to predict
metastatic disease. These markers will be compared
with the best indicators of increased risk for malig-
nancy suggested by the WHO, i.e. tumor size and
proliferation index. For this purpose we have extended
our previously analyzed collection of mainly benign
insulinomas (Speel et al. 2001) to a large group of 62
tumors, including 18 malignant cases. In addition,
these tumors were examined for MEN1 mutations to
assess the impact of this gene in insulinomas, and a
possible association of such mutations with particular
CGH proﬁles.
Materials and methods
Tumor material and patient data
Sixty-two insulinomas (32 females, mean age 52.1t
18.6 years and 30 males, mean age 53.1t15.7 years)
were selected from the archives of the Departments of
Pathology of the University Hospital, Zurich, Switzer-
land and the University Medical Centers of Rotterdam,
Utrecht and Nijmegen, The Netherlands. The study
protocol was approved by the institutional ethical
committee, and all of the patients gave informed
consent. The samples included 59 frozen and three
parafﬁn-embedded insulinomas, which were all spora-
dic tumors and not associated with the inherited
MEN1 syndrome. The tumors were classiﬁed accord-
ing to the most recent WHO classiﬁcation (Kommi-
noth et al. 2004). All insulinomas had hyperinsulinism
followed by a hypoglycemia syndrome. Forty-four
of the patients had localized disease, deﬁned by (i)
the absence of extra-pancreatic spread of the tumor
as evidenced by computed tomography, magnetic
resonance imaging or ultrasound scanning, and (ii) a
complete absence of hypoglycemia (even during 72 h
fasting) after successful removal of the tumor by
surgery. Moreover, during follow-up of at least 1 year,
these cases showed neither evidence of recurrent hypo-
glycemia at follow-up, nor recurrence or metastases by
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radiology. No post-operative adjuvant therapy was
given to these patients. Eighteen patients had advanced
disease, with tumor spread into the surrounding soft
tissue, lymph nodes or liver.
DNA extraction
DNA extraction was performed as described before
(Speel et al. 2001). Genomic DNA from frozen samples
was isolated by homogenizing approximately 5mm3 of
each sample prior to proteinase K treatment and DNA
puriﬁcation using the QIAamp DNAmini kit (Qiagen).
Genomic DNA from parafﬁn-embedded tumor mate-
rial was isolated from 5–10mm thick tissue sections by
this procedure after deparafﬁnation. DNA quality was
checked with agarose gel electrophoresis and quanti-
ﬁed by spectrophotometry.
CGH and digital image analysis
CGH was performed with DNA isolated from the 62
insulinoma samples as previously described (Speel et al.
2001). Brieﬂy, 2mg tumor DNA were labeled with
Spectrum Green-dUTPs (Vysis, Downers Grove, IL,
USA) by nick translation (BioNick labeling kit; Life
Technologies). Spectrum Red-labeled normal and sex-
matched reference DNA (Life Technologies) was used
for co-hybridization. The hybridization mixture con-
sisted of 800 ng Spectrum Green-labeled tumor DNA,
800 ng Spectrum-Red labeled reference DNA and
15mg human Cot-1 DNA (Life Technologies) dissolved
in 12ml hybridization buffer (50% formamide,
2rSSC, 10% dextran sulfate, pH 7.0). Hybridization
was carried out for 3 days at 37 xC to denatured (5min
at 75 xC in 70% formamide/2rSSC, pH 7.0) normal
male human metaphase spreads (Vysis). Slides were
washed twice at 45 xC for 5min in 50% formamide/
2rSSC, pH 7.0, followed by 5min in PBS at room
temperature. The chromosomes were counterstained
with 0.2mg 4,6-diamidino-2-phenylindole per ml Vecta-
shield (Vector) for identiﬁcation.
Digital images were collected from at least ten
metaphases using the Metasystems Image Pro System
black and white CCD camera (Altlussheim, Germany)
mounted on top of a Leica DMRE ﬂuorescence
microscope, equipped with DAPI, Spectrum Green,
and Spectrum Red ﬁlter sets. The software Meta-
systems ISIS 4.4.25 program was used to calculate
average green-to-red ratio proﬁles for each chromo-
some. At least ten observations per autosome and ﬁve
observations per sex chromosome were included in
each analysis. Gains and losses of DNA sequences
were deﬁned as chromosomal regions where the mean
green-to-red ﬂuorescence ratio was above 1.20 and
below 0.80 respectively. Over-representations were
considered ampliﬁcations when the ﬂuorescence ratio
values in a subregion of a chromosomal arm exceeded
1.5. In negative control hybridizations, the mean
green-to-red ratio occasionally exceeded the ﬁxed 1.2
cut-off level at the following chromosomal regions:
1p32-pter, 16p, 19 and 22. Gains of these G-C-rich
regions were therefore excluded from all analyses.
Statistical analysis of CGH results
The relationship between genomic alterations and
malignancy was analyzed by using the chi-square test
or the Fisher exact test, as appropriate. ANOVA was
applied to compare the number of genomic alterations
between benign and malignant insulinomas. A sig-
niﬁcance level of P £ 0.05 was chosen.
Confirmation of CGH data by fluorescence
in situ hybridization (FISH) analysis
To validate CGH data independently, touch prepara-
tions of 15 insulinomas were subjected to FISH as
described previously (Go¨rtz et al. 1999, Speel et al.
2001). The following probe combinations were applied:
(i) centromere 9 (pMR9a) and a cosmid probe (c-ABL-
8) containing the cAbl gene on chromosome 9q34,
(ii) centromere 6 (p308) and a PAC probe (66H14)
mapping to the 6q21 region, and (iii) centromere 11
(pLC11A) and a cosmid probe (c10B11) containing the
MEN1 gene at 11q13. Digoxigenin-labeled probes were
detected by sheep anti-digoxigenin ﬂuorescein- (Roche)
and biotin-labeled probes by two layers of avidin-
rhodamine connected by a biotinylated goat anti-
avidin antibody (Vector). Probe visualization and
nuclear counterstaining were carried out as described
for CGH, and signal scoring and evaluation was
performed as described previously (Go¨rtz et al. 1999,
Barghorn et al. 2001a).
MEN1 mutation analysis
MEN1 is a 9 kb gene which encompasses ten exons
(ﬁrst exon untranscribed). The remaining nine coding
exons were examined in 43 insulinomas, 31 benign and
12 malignant tumors, by denaturing gradient gel
electrophoresis (DGGE) and single-strand conﬁrma-
tion polymorphism (SSCP), as previously used in
several studies (see Table 1) (Go¨rtz et al. 1999, Perren
et al. 2002). PCR ampliﬁcations were carried out using
a programmable thermal cycler (DNA thermal cycler
9600; Perkin Elmer, Norwalk, CT, USA). After initial
denaturation at 94 xC for 5–10min, the DGGE PCR
Endocrine-Related Cancer (2005) 12 435–447
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procedure comprises 40 cycles of denaturation at 94 xC
for 1min, annealing at 55–67 xC (see Table 1) for 1min
and extension at 72 xC for 1min. Finally, PCR tubes
were incubated at 72 xC for 10min, at 98 xC for 8min,
at 55 xC for 30min, at 37 xC for 30min, and than at
0 xC. The SSCP PCR procedure used the following
incubations: 35 cycles of denaturation at 94 xC for 75 s,
annealing at 55–67 xC (Table 1) for 90 s and extension
at 72 xC for 2min. Finally, PCR tubes were incubated
at 72 xC for 5min and than at 4 xC. PCR ampliﬁcations
were performed in 50ml reactions with 1 ng genomic
DNA, 1rPCR buffer (Roche), 1.5mMMgCl2, 0.2mM
dNTPs, 50 pmol of each forward and reverse primer
and 1U Amplitaq Gold (Roche).
For the DGGE analysis, 10% polyacrylamide gels
with a 20–80% (in the case of exon 10a: 50–90%)
denaturing gradient were used. A solution of 100%
chemical denaturant consists of 7M urea and
40% formamide. The gels polymerized by adding 1%
ammonium persulfate and 0.05% tetramethylethylene-
diamine. Once the gradient gel has polymerized, a 10%
polyacrylamide stacking gel is layered on top of this
gradient gel; 10ml PCR-ampliﬁed DNAwas mixed with
3ml PCR-ampliﬁed non-mutated DNA, denatured,
annealed, and loaded on the gel together with 5ml
Ficoll loading buffer. Electrophoresis was performed
at 100V for 15 h. After electrophoresis the DNA was
visualized by silver staining as previously described
(Go¨rtz et al. 1999). Patient DNAs with an altered
migration pattern on the DGGE gel were ampliﬁed
again with primers without a GC-clamp, puriﬁed using
the QIAquick PCR puriﬁcation kit (Qiagen), and
subjected to DNA cycle sequencing in sense and anti-
sense direction using the TaqDyeDeoxy Terminator
Cycle Sequencing kit (Applied Biosystems, Weiterstadt,
Germany). This was followed by gel electrophoresis,
data collection, and analysis on an automated DNA
sequencer (Model 373A; Applied Biosystems).
For SSCP analysis, 10ml denatured PCR products in
stop buffer (95% formamide, 20mM EDTA, 0.05%
xylene cyanol, 0.05% bromophenol blue) were loaded
onto non-denaturing 6% polyacrylamide and 5%
glycerin gels. Electrophoresis was carried out for 16 h
at 8W and 500–700V at room temperature. After
electrophoresis the DNA was visualized by silver
staining. PCR products with an altered migration
pattern on a SSCP gel were further puriﬁed and
sequenced as described above for DGGE.
Table 1 Primers used for MEN1 mutation analysis (exons 2–10): modified from a previous study (Go¨rtz et al. 1999)
Primer Sequence Length Technique
Annealing
temperature (xC)
M2cnewF 5k-CCCGCTTCACCGCCCAGAT-3k 272 DGGE 55
M2cnewR 5k-TGGAGGGTTTTGAAGAAGTGGGTCA-3k
M2newF 5k-CCTTAGCGGACCCTGGGA-3k 365 SSCP 58
M2newR 5k-ATAGAGGGCGGCGATGATAGA-3k
M2NNF 5k-TCAACCGCGTCATCCCTACC-3k 405 SSCP 62
M2NR 5k-CACCTGCCGAACCTCACAAG-3k
M3F 5k-GCACAGAGGACCCTCTTTCAT-3k 335 DGGE 55
M3R 5k-CTACAGTATGAAGGGGACAAGG-3k
M4F 5k-TGGGCCATCATGAGACATAA-3k 272 DGGE 55
M4R 5k-CCCACAGCAAGTCAAGTCTG-3k
M5F 5k-CCTGTTCCGTGGCTCATAAC-3k 148 DGGE 55
M5R 5k-CCTGGCCACTTCCCTCTA-3k
M6F 5k-GGTGGCAGCCTGAATTATGA-3k 213 DGGE 55
M6R 5k-TTAGGGTCTCCCTTCTGCAC-3k
M7F 5k-GGTGGGAGTGGAGATGGAGAGG-3k 398 DGGE 55
M7R 5k-GGACGAGGGTGGTTGGAAACTG-3k
M8NF 5k-AGACCCCTTCAGACCCTACAGAG-3k 273 SSCP 67
M8R 5k-CCATCCCTAATCCCGTACATGC-3k
M9F 5k-CTGCTAAGGGGTGAGTAAGAGAC-3k 334 DGGE 55
M9R 5k-AAAAGTCTGACAAGCCCGTG-3k
M10NF 5k-TTGCTCTCACCTTGCTCTCC-3k 409 SSCP 56
M10NNR 5k-CTTGATGGCGCTCGAGTT-3k
M10a F 5k-CCTTGCTCTCACCTTGCTCT-3k 392 DGGE 55
M10aR 5k-TCTGGAAAGTGAGCACTGGA-3k
M10b F 5k-GAGGGTCCAGTGCTCACTTT-3k 423 DGGE 55
M10bR 5k-GGGTTCTGAGCTGGAGAAAA-3k
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Ki67 immunohistochemistry
Ki67 antigen staining was performed on 4mm thick
parafﬁn-embedded tissue sections of 35 insulinomas
(22 benign and 13 malignant) as described previously
(Wessels et al. 2004). Brieﬂy, sections were deparafﬁn-
ized and treated with 10mM citrate buffer (pH 6.0) in
a microwave oven at 600W for 15min (antigen
retrieval). Endogenous peroxidase was inactivated by
treatment with 2% H2O2 in methanol, followed by
incubation in 3% BSA/PBS to block non-speciﬁc
binding of antibody conjugates. The sections were
incubated for 30min at 37 xC with the mouse mono-
clonal antibody MIB-1 directed against Ki67 (Dako)
at a 1 : 100 dilution in 1% BSA/PBS, biotin-labeled
horse anti-mouse antibody at a 1 : 200 dilution, and
avidin-biotinylated peroxidase complex (Vector
Laboratories, Burlingame, CA, USA) at a 1 : 50 dilution
in 4rSSC. Peroxidase activity was visualized using
diaminobenzidine/H2O2 (Sigma Chemical Co.) and
sections were counterstained with hematoxylin and
mounted in Entellan (Merck, Darmstadt, Germany).
Positive and negative control tissues were included.
Positive nuclei were scored in at least 500 cells per
sample. The Ki67 labeling index was expressed as the
percentage of total cells that were immunopositive.
Results
General CGH findings
Figure 1 summarizes the DNA copy number changes
detected by CGH in the 62 insulinomas. Genomic
aberrations were found in 33 of the 44 benign and all
malignant insulinomas. The average number of chro-
mosomal aberrations per tumor was 7.2t7.0 (range
0–28). Chromosomal gains (mean 3.9) were more
common than chromosomal losses (mean 2.8), and in
two tumors ampliﬁcations were identiﬁed, i.e. at 9q34
(2r) and 4p16 (1r). The most frequently involved
speciﬁc genomic changes (in >20% of insulinomas)
included loss of Xq in female patients (smallest region
of interest (SRI): Xq21) (34%) and Y in male patients
(43%), and gains of chromosomes 5q, 7pq, 9q, 17 and
20q, with the highest frequency of gains for chromo-
some 9q (58%). Interestingly, gain of chromosome 9q
was detected at approximately the same frequency
in both benign and malignant tumors (57 vs 61%
respectively) with 9q34 most commonly included.
When these tumors are compared with those without
9q alterations, the total number of aberrations and
gains per tumor were signiﬁcantly higher in the former
group (9.1t6.2 vs 4.6t7.3, P=0.001; and 5.5t4.3 vs
1.7t3.1, P<0.0001 respectively), with gains of 7pq, 9p
and 20q and loss of Xpq more frequently detected.
The obtained CGH results were validated in 15
insulinomas by FISH using chromosome 6-, 9- and
11-speciﬁc probe sets (Table 2 and Fig. 2). In general,
the FISH results conﬁrmed our CGH ﬁndings. Tumors
without CGH alterations exhibited two or sometimes
three copies of chromosome targets, indicating a
diploid and triploid DNA content respectively
(patients 1–7, 11–13), or showed alterations in small
subpopulations (20%) of cells (e.g. 11q13 loss in
patients 2, 14 and 15). In the case of 9q alterations,
always ‡3 copies of the 9q34-speciﬁc region were
observed including two cases with an ampliﬁcation
(patients 10 and 15). Four cases showed tumor
subpopulations with aberrant copy numbers of chro-
mosome 9 targets indicating genetic heterogeneity
(patients 10–12, 15).
CGH findings, tumor size and proliferation
index in relation to metastatic disease
The total number of chromosomal changes, gains and
losses all are strongly associated with malignancy
(P<0.0001; Table 3A). In addition, marked differences
in chromosome-speciﬁc alterations were observed
between benign and malignant tumors (Fig. 1 and
Table 3A). Particularly, losses of 2q, 3q, 6pq and 10q
and gains of 4q, 7q, 12pq, 14q, 15q, 17pq, and 20pq
were detected signiﬁcantly more frequent in malignant
insulinomas, with 6q loss (SRI: 6q14 and 21–22) (0%
in benign vs 67% in malignant insulinomas), 12q gain
(SRI: 12q24) (2% vs 50%), 14q gain (5% vs 50%) and
17pq gain (5 and 9% vs 56 and 61% respectively)
correlating most evidently (in all cases P<0.0001). If
the tumors are grouped according to the presence of
9q gains, the best common markers for malignancy are
6q loss and 7q, 14q and 17q gains (Table 3B). In
addition, a number of genomic changes were exclu-
sively identiﬁed in one or the other insulinoma group.
Interestingly, the group with 9q gain shows gains and
the group without 9q gain predominantly losses as
parameters associated with malignancy (Table 3B).
Apart from differences in genomic alterations,
benign insulinomas were found to be signiﬁcantly
smaller than malignant ones (diameter=1.5 vs 3.8 cm
respectively, P<0.0001). Because a diameter of 2 cm is
an important parameter in insulinoma classiﬁcation,
we compared tumors with a size<2 cm with tumors
‡2 cm in diameter. This comparison revealed that an
increase in the total number of aberrations, gains and
losses was signiﬁcantly correlated with a size ‡2 cm
(Table 3A). Loss of 3q, 6pq and 22q and gains of 5pq,
Endocrine-Related Cancer (2005) 12 435–447
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Benign insulinomas (n=44)
Malignant insulinomas (n=18) 
1 3 4 5 6 7 8 9 10 
11 12 13 14 15 16 17 18 19 20 21 22 X Y
2 
1 3 4 5 6 7 8 9 10 
11 12 13 14 15 16 17 18 19 20 21 22 X Y
2 
Figure 1 Summary of all DNA copy number changes detected by CGH in 44 benign and 18 malignant insulinomas. Vertical
lines on the left of the chromosome ideograms indicate the number of cases showing losses of the corresponding chromosomal
regions; vertical lines on the right indicate the number of cases showing gains. The bold lines represent amplifications at 4pr6
and 9q34. Gains on 1p32-pter, 16p, 19, and 22 were not analyzed (see text).
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7q, 12q, 14q, 17pq and 21q were also signiﬁcantly
correlated with a tumor size ‡2 cm (Table 3A).
Another indicator of risk of malignancy is a
proliferation index of ‡2% measured by immuno-
histochemistry of Ki67 (MIB-1 monoclonal antibody).
Comparison of 22 benign and 13 malignant insulino-
mas revealed only one benign and four malignant
insulinomas showing a proliferation index ‡ 2%. This
ﬁnding did not reach statistical signiﬁcance when
comparing benign and malignant tumors. Gain of
chromosome 12q was the only parameter signiﬁcantly
correlated with a proliferative rate of ‡ 2% (60 vs 13%
in the group with a proliferation index<2% respec-
tively, P=0.044).
Table 4 shows these parameters as markers in
univariate and bivariate analysis with the percentages
of correctly classiﬁed tumors (sensitivity and speciﬁ-
city) and their odds ratios. The best classiﬁcation
markers for malignant behavior according to sensitiv-
ity in univariate analysis are the total number of
aberrations (‡8), gains (‡5) and the size of the tumor
(‡2 cm in diameter). A combination of the total
number of gains (‡5) and losses (‡5) provides an even
better sensitivity as shown by bivariate analysis with
two independent markers.
MEN1 mutation analysis
MEN1 mutation analysis was performed on 43
sporadic insulinomas from which sufﬁcient DNA was
available. Only one insulinoma (male, 42 years old)
showed a somatic 7 bp deletion in exon 10 (position
1527) of theMEN1 gene, as shown in Fig. 2D–F. CGH
analysis of this benign tumor showed gains of 5pq, 6pq
and 21q. Although loss of chromosome 11q was not
identiﬁed by CGH, FISH analysis revealed loss of the
MEN1 gene in 20% of cells (see above and Table 2,
patient 14) suggesting deletion of the wildtype locus. A
known polymorphism in exon 2 (S145S) was found in
an additional tumor.
Discussion
We have performed a comprehensive genome-wide
survey of DNA copy number changes in a series of 62
human sporadic insulinomas with the goal to identify
genetic alterations that discriminate benign tumors
from cases with metastatic progression. Particularly
the CGH detection of a high number of conﬁned
chromosomal alterations per tumor was found to
strongly correlate with metastatic disease in this EPT
subtype. In addition, this study provides further
evidence that gain and/or ampliﬁcation of chromo-
some 9q, rather than MEN1 mutations, is a frequent
event in sporadic insulinomas that may be of
pathogenetic importance.
Our data strongly indicate that insulinoma progres-
sion is driven by the accumulation of genetic changes,
as is also known to occur in other types of human
carcinomas (Nowak et al. 2002, Draviam et al. 2004,
Vogelstein & Kinzler 2004). A marked distinction
between benign and malignant insulinomas can be
made on the basis of the number of genomic
Table 2 Double-target FISH results in 14 benign (cases 1–14) and one malignant (case 15) insulinomas
Tumor CGH chr 6 6C:6q21a CGH chr 9 9C:9q34a CGH chr 11 11C:11q13a
1 0 2 : 2 0 2 : 2 11pq- 1 : 1
2 0 2 : 2 0 2 : 2 0 2 : 1 (26%)
3 0 2 : 2 0 2 : 2 0 2 : 2
4 0 2 : 2 0 2 : 2 0 2 : 2
5 0 2 : 2 0 2 : 2(41%), 3 : 3 (30%) 0 2 : 2
6 0 2 : 2 0 2 : 2, 2 : >2 (27%) 0 2 : 2
7 0 2 : 2 0 2 : 2 0 2 : 2
8 0 2 : 2 9qrg+ 2 : 3 0 2 : 2
9 0 2 : 2 9q34+ 3 : 3 0 2 : 2
10 0 2 : 2 9pq+
9q34+
Area 1 : 3 : 3
Area 2 : 3 : 5, 3:>5 (Amp)
11q13+ 2 : 3
11 0 3 : 3 9q34+ 3 : 3 (37%), 4 : 4 (37%) 0 2 : 2
12 0 3 : 3 9q32 - 34+ 3 : 3 (42%), 3 : 4 (24%) 11pq- 2 : 2
13 0 3 : 3 9q34+ 3 : 6 0 3 : 3
14 6pq+ 3 : 3 0 2 : 2 0 2 : 1 (20%)
15 6q- 2 : 1 (34%) 9q+
9q34+
4 : 4 (44%), 4 : 8 (25%)
2 : 12 (5%; Amp)
0 2 : 1 (22%)
aFISH results: 2–1 (n%), 2 copies of the centromere probe and 1 copy of the locus-specific probe in n% of nuclei (in the case of
subpopulation of cells); Amp, amplification.
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alterations per tumor as identiﬁed by CGH. The most
prominent DNA copy number changes enabling this
differentiation include loss of chromosome 6q (SRI
6q14 and 6q21-22) and gains of 7q, 12q (SRI 12q24),
14q and 17pq. In comparison with currently used
indicators of malignancy, including tumor size >2 cm
and proliferative index ‡2%, high numbers of chro-
mosomal alterations are signiﬁcantly more powerful
for this purpose (Table 4). The most potential
indicators for metastatic progression detected in our
study include: (i) a combination of gains and losses
(both ‡5 per tumor), (ii) the total number of aberra-
tions (‡8 per tumor), (iii) a combination of losses (‡ 5
per tumor) and 17q gain, and (iv) the total number of
gains (‡5 per tumor). Thus, our data suggest that
chromosomal instability (CIN), an abnormal cell state
with elevated chromosomal gains and losses, is the
optimal predictor for malignant progression in spora-
dic insulinomas. It will be interesting to identify the
target genes that might be involved in the development
of CIN (Draviam et al. 2004).
The identiﬁed chromosomal regions altered in
insulinomas point to loci containing putative onco-
genes and tumor suppressor genes. The most frequent
aberration identiﬁed by CGH in about 60% of both
benign and malignant insulinomas is the increase of
chromosome 9q copy numbers. This extends our
previous ﬁndings in a small group of benign insulino-
mas and endorses the importance of this genetic event
in early tumor development (Speel et al. 2001).
Moreover, insulinomas with 9q gain harbored a
signiﬁcantly higher number of aberrations, especially
gains, than the remaining tumors, and this difference in
genetic makeup suggests the evolution along two
different genetic pathways in insulinoma development.
The SRI is located at 9q34 and this region was found
ampliﬁed in two insulinomas. Gain and/or ampliﬁca-
tion of this region have been reported in other
B CA 
D E F 
Figure 2 Results of representative examples of insulinoma cases examined by FISH (see Table 3) and MEN1 mutation
analysis. (A) Loss of 6q21 (green; arrow) with respect to centromere 6 (red) in patient 15. (B) Gain and amplification of 9q34
(red) with respect to centromere 9 (green; arrow) in patient 10. (C) Loss of 11q13 (green; arrow) with respect to centromere 11
(red) in patient 2. (D) SSCP analysis of exon 10 of the MEN1 gene in seven tumors with a negative control (lane 1) and a
positive control (lane 2). Lane 8 represents DNA from patient 14 (Table 3) harboring a MEN1 mutation. (E) The normal MEN1
sequence profile of exon 10, with the part deleted in (F) between the vertical lines. (F) Sequence profile of patient 14 with the
MEN1 mutation, a 7bp deletion (GTCGCTG) in exon 10.
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neoplasms, including neuroendocrine tumors (Dannen-
berg et al. 2000, Figueiredo et al. 2000, Garcia et al.
2002), schwannomas (Warren et al. 2003), and entero-
pathy-type T-cell lymphomas (Baumga¨rtner et al.
2003). There are several candidate genes localized in
this region, i.e. the oncogene VAV2 (Booden et al.
2002), CDK9, a co-regulator of the progression
through the cell cycle (Napolitana et al. 2002),
Notch-1, a transmembrane receptor promoting differ-
entiation of T-cells (Aster et al. 2000), LMX1B, a LIM-
homeodomain-containing protein involved in a variety
of developmental events (Hobert & Westphall 2000),
Table 3 Parameters associated with malignancy and tumor size (A) or 9q gain (B)
A
Benign (n=44) Malignant (n=18) P Size <2cm (n=40) Size ‡ 2 cm (n=22) P
Total aberrations 4.2t4.6 14.1t6.7 <0.0001a 4.7t4.8 11.9t8.0 <0.0001a
Losses 1.7t2.5 5.7t4.5 <0.0001a 1.7t2.5 5.0t4.5 <0.0001a
Gains 2.5t3.3 7.3t4.4 <0.0001a 2.8t3.1 6.1t5.2 <0.0001a
Mean size (cm) 1.5t0.5 3.8t2.3 <0.0001a — — —
2q loss 5% 39% 0.002c 8% 27% NSb
3q loss 0% 33% <0.0001c 3% 23% 0.010b
4q gain 0% 22% 0.005c 0% 18% 0.025b
5p gain 11% 28% NSc 8% 32% 0.033b
5q gain 16% 39% NSc 13% 41% 0.025b
6p loss 0% 28% 0.001c 0% 23% 0.008b
6q loss 0% 67% <0.0001c 5% 45% <0.0001b
7q gain 18% 67% 0.001c 20% 55% 0.012b
10q loss 0% 22% 0.005c 0% 18% 0.025b
12p gain 0% 22% 0.005c 0% 18% 0.025b
12q gain 2% 50% <0.0001c 8% 32% 0.033b
14q gain 5% 50% <0.0001c 5% 41% 0.001b
15q gain 7% 33% 0.014c 8% 27% NSb
17p gain 5% 56% <0.0001c 10% 36% 0.029b
17q gain 9% 61% <0.0001c 13% 45% 0.010b
20p gain 7% 28% 0.039c 8% 23% NSb
20q gain 11% 50% 0.002c 18% 32% NSb
21q gain 9% 17% NSc 3% 27% 0.011b
22q loss 5% 22% NSc 3% 23% 0.033b
B
Parameter
Insulinomas with 9q gain
Parameter
Insulinomas without 9q gain
Benign (n=25) Malignant (n=11) P Benign (n=19) Malignant (n=7) P
Common parameters
6q loss 0% 64% <0.0001c 6q loss 0% 71% <0.0001c
7q gain 32% 73% 0.034c 7q gain 0% 57% 0.002c
14q gain 8% 45% 0.018c 14q gain 0% 57% 0.002c
17q gain 16% 73% 0.002c 17q gain 0% 43% 0.013c
Group-specific parameters
12p gain 0% 27% 0.023c 1p loss 5% 57% 0.010c
12q gain 4% 64% <0.0001c 2q loss 0% 43% 0.013c
13q gain 0% 27% 0.023c 3q loss 0% 57% 0.002c
17p gain 8% 73% <0.0001c 6p loss 0% 57% 0.002c
20q gain 20% 64% 0.020c 21q loss 0% 43% 0.013c
22q loss 5% 57% 0.010c
Y loss 5% 57% 0.010c
5q gain 5% 57% 0.010c
aANOVA analysis.
bchi-square test.
cFisher exact test.
NS=not significant.
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TSC1, the tuberous sclerosis gene 1, and cAbl, playing
a role in chronic myeloid leukemia (Goldman & Melo
2003). In TSC patients, insulinomas are occasionally
detected. In these tumors, mutations in TSC1 or TSC2
(at 16p13.3) in combination with loss of the wildtype
allele result in stimulation of cell growth and prolifera-
tion via dysregulation of mTOR activity (Davoren &
Epstein 1992, Yong et al. 2004). In our series of
insulinomas we noticed often ‡3 copies of 9q34 instead
of loss. The intriguing ﬁnding that duplication/
ampliﬁcation of mutated alleles may also lead to
tumorigenesis (Zhuang et al. 1998) should be examined
in this respect. The oncogenic signiﬁcance of the cAbl
gene in insulinomas is unknown, although we identi-
ﬁed two cases with ampliﬁcation of this locus by FISH
analysis, and cAbl overexpression has been reported in
two rat insulinoma cell lines (DeAizpurua et al. 1997).
Additional research is needed to clarify its possible role
in the development of insulinomas.
Despite the importance of MEN1 gene mutations in
EPTs, we only identiﬁed one case with a MEN1
mutation in a group of 43 insulinomas. In this tumor
the wildtype allele was also lost. This ﬁnding is in
agreement with other studies suggesting a minor role
for MEN1 in human insulinomas (Zhuang et al. 1997,
Go¨rtz et al. 1999, Cupisti et al. 2000, Gumbs et al.
2002, Moore et al. 2003). However, other mechanisms
of gene inactivation may be involved in insulinoma
development. Promoter hypermethylation of the
MEN1 gene has not been detected so far (Chan et al.
2003). The many different candidate proteins found to
interact with menin may also implicate that other
mechanisms can lead to down-regulation of the MEN1
protein (Chandrasekharappa & Teh 2003). This needs
to be further investigated using, for example, RT-PCR
or immunohistochemistry (Cavallari et al. 2003). The
high frequency of loss of heterozygosity in EPTs,
including insulinomas, may also point to additional
tumor suppressor gene loci at 11q (Chakrabarti et al.
1998, Speel et al. 2002).
Chromosome 6q loss proved to be the strongest
chromosome-speciﬁc marker to classify the metastatic
potential of insulinomas, because it was only detected
in the malignant tumors. This is in agreement with a
previous study, in which we mapped the SRI to
6q22-24 in sporadic EPTs in general (Barghorn et al.
2001b). Several candidate tumor suppressor genes are
located in the common region of deletion, including
AIM1 (absent in melanoma 1), a beta-gamma-
crystallin superfamily member inhibiting cellular
growth by possible interactions with the cytoskeleton
(Ray et al. 1997), CCNC (cyclin C) (Polly et al. 2000),
PTPRK (receptor-type protein-tyrosine phosphatase
kappa), possibly involved in the regulation of cell
contact and adhesion via dephosphorylation of
catenins or cadherins (Yang et al. 1996), CX43
(connexin 43), a gap junction protein involved in
intercellular communication (Mesnil 2002), and LOT1
(PLAGL1/ZAC1). LOT1 is a zinc-ﬁnger nuclear
transcription factor that regulates the type 1 receptor
for pituitary adenylate cyclase-activating polypeptide,
an important mediator of autocrine control of insulin
secretion in the pancreatic islet. Furthermore, it
possesses anti-proliferative effects and appears to be
epigenetically silenced in different types of cancer,
including parathyroid adenomas (Pagotto et al. 2000,
Abdollahi et al. 2003). Future studies will determine if
these genes are involved in insulinoma oncogenesis.
Table 4 Parameters for assessing malignant behavior
Parameter Specificitya Sensitivityb OR (95% CI)
Univariate analysis
Total no. of aberrations ‡ 8 82 83 22.5 (5.2–96.6)
Total no. of gains ‡ 5 89 78 27.3 (6.4–116.3)
Total no. of losses ‡ 5 89 50 7.8 (2.1–29.0)
6q loss 100 67 >86 (9.4–785.2)
14q gain 95 50 21 (3.9–114.1)
17q gain 91 61 15.7 (3.9–63.6)
Size ‡ 2 cm 82 76 15.8 (4.1–60.7)
Proliferative index (Ki67) ‡ 2% 95 31 9.3 (0.9–95.6)
Bivariate analysis
Total no. of gains ‡ 5, and total no. of losses ‡ 5 77 89 20.9 (4.5–96.0)
17q gain, and total no. of losses ‡ 5 80 83 15.8 (4.0–61.6)
OR=odds ratio, 95% CI=95% confidence interval.
aPercent of benign tumors without the parameter.
bPercent of malignant insulinomas with the parameter.
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Deletions of other chromosomal regions that were
reported to be associated with malignant behavior of
EPTs, such as 1p, 3p, 3q, 11q, 17p, 22q and X (Chung
et al. 1997, 1998, Beghelli et al. 1998, Ebrahimi et al.
1999, Hessman et al. 1999, Barghorn et al. 2001a, b,
Guo et al. 2002, Missiaglia et al. 2002, Wild et al.
2002), were only occasionally observed in this CGH
study on insulinomas. Losses of chromosome 3p and
3q were identiﬁed signiﬁcantly more frequently in the
malignant insulinomas, but only at low frequencies of
17 and 33% respectively. This holds also true for the
association of 1p and 22q losses with malignancy in the
group of insulinomas without 9q gain. These results
indicate that the reported alterations are infrequent in
insulinomas. However, it cannot be excluded that small
deletions and gains are missed by CGH analysis due to
the resolution of 5–10Mb. This might also under-
score to some extent the frequency of alterations yet
identiﬁed in this study. Gains of chromosomes 7pq,
12q, 14q and 17pq have been frequently reported in
many types of cancer and are also commonly observed
in sporadic gastrointestinal neuroendocrine tumors,
including EPTs (Knuutila et al. 1998, Terris et al. 1998,
Stumpf et al. 2000, To¨nnies et al. 2001, Zhao et al.
2001). However, so far no convincing evidence has
been presented of speciﬁc genes on these chromosomes
playing a role in EPTs in general or insulinomas in
particular (Speel et al. 1999, Goebel et al. 2002).
In summary, our data show that benign insulinomas
can be efﬁciently distinguished from tumors with
metastatic progression on the basis of the chromo-
somal proﬁle of the tumors. Furthermore, because
these alterations are recurrently detected by CGH, the
identiﬁed chromosomal regions may harbor candidate
cancer genes that are important in insulinoma patho-
genesis. Whereas the presence of 9q gain and/or
ampliﬁcation appears to be an important genetic event
in insulinoma development, theMEN1 gene is unlikely
to be involved in this process.
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